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The fields of artificial intelligence (AI) and information and communication technology 
(ICT) are currently witnessing remarkable progress, and they are now being applied to 
systems that encourage people to engage in voluntary health promotion behaviors. In the 
future, health intervention systems will likely be replaced by AI. The development of such AI-
based health intervention systems is still in its infancy, however, and there is little evidence of 
their effectiveness. The purpose of this study is to estimate the macro health care cost savings 
that would result from the widespread use of AI-based health intervention systems. This study 
to estimates the healthcare cost reductions that could be achieved if AI interventions were to 
spread and the number of obese people were to decrease, based on the estimates of Okaniwa 
and Yoshida (2020). It was estimated that AI interventions could reduce medical costs for 
diabetes and hypertensive diseases by 8.2% and 7.2%, respectively. The findings of this paper 
could contribute to providing preliminary material for new developments in future research 
in this field. 
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Obesity is a public health threat in developed countries. In Japan, lifestyle-related diseases, 
including obesity, account for more than 30% of medical costs (Ministry of Health, Labour 
and Welfare, 2018a). Medical costs are 22.3% higher in obese groups than in non-obese 
groups (Kuriyama et al., 2002), and maintaining a 10% weight loss reduces one’s lifetime 
medical costs by US$2,200-5,300 (Oster et al., 1999). Asians, in particular, are more prone 
to diabetes following even a small increase in Body Mass Index (BMI), compared to other 
ethnic groups (Sone et al., 2004). 
In this context, the Japanese government is stepping up its assistance for research into 
the development of new service models and platforms for data management and utilization 
for serious lifestyle-related diseases and nursing care prevention. In recent years, the 
widespread use of cloud computing and mobile devices (e.g., smartphones) has made it 
possible to utilize personal health records (PHRs), which comprise the medical, nursing, and 
health data of individuals, for various services, with the consent of the individual. In addition, 
information and communication technology (ICT) and artificial intelligence (AI) are now 
being considered in the context of providing health interventions. Using ICT and AI could 
potentially reduce the costs of traditional direct human interventions, and could reach a large 
number of people. However, there is little evidence regarding the effectiveness of AI-based 
health intervention systems. 
Okaniwa and Yoshida (2020) conducted an intervention experiment1 and tested the 
effectiveness of AI-based health interventions. In the experiment, they used a smartphone-
based diet management application (app) for the intervention. Users took photos of their 
meals with their smartphone’s camera, and the app analyzed the photos, determined the 
nutrients and calories in their meals, and calculated a meal balance score. The app also 
delivered advice on balanced meals, supervised by nutritionists, and created by the AI's 
algorithm. The analysis revealed that the intervention from the AI-delivered text advice 
significantly lowered the participants’ BMIs by 2.6%. This paper uses the results from this 
previous study to estimate the effect such an AI-delivered service on reducing medical costs. 
In other words, this study estimated the macro medical cost savings of AI-delivered text 
message interventions becoming more widespread (and thus the prevalence of obesity 
decreasing). This paper will contribute to providing preliminary material for new 
developments in future research in this field. 
 
1 The experiment was conducted for three months, from February to April 2020. The subjects 
were recruited from 102 users of asken Inc.'s diet management app. For details of the experiment, 
please refer to Okaniwa and Yoshida (2020).  
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2. DATA AND METHODS 
Okaniwa and Yoshida (2020) found that an AI-delivered text advice intervention significantly 
lowered participants’ BMIs by 2.6% in three months. In this study, this estimate was used to 
examine the medical cost savings that could be achieve if people's health were to be improved 
using these interventions. Obesity increases the risk of diabetes, hypertensive diseases, and 
hyperlipidemia (Kadowaki et al., 1984; Ohnishi et al., 2006; Kadowaki et al., 2006) and causes 
atherosclerosis (Iwabu et al., 2010). Obesity interventions have been found to prevent the 
onset of these illnesses (Kosaka et al., 2005). If AI and human interventions, such as those 
examined in our study, were to become widely used, people's BMIs might decrease. This could 
reduce the prevalence of obesity in the population, and therefore the number of people with 
obesity-related diseases. Thus, medical costs could be reduced. 
Estimating how many people would no longer be obese following such an intervention 
requires data on the BMI distribution of the population. BMI is calculated in units of kg/m2, 
where kg is a person's weight in kilograms and m2 is their height in meters, squared. According 
to the Japan Society for the Study of Obesity (JSSO, 2011), obesity comprises by a BMI of 25 
or higher and a visceral fat area ≥100 cm2 (as measured by computed tomography). In this 
paper, individuals with a BMI of 25 or higher were considered to be obese, and the number 
of people who could have their BMI reduced to below 25 by the intervention was estimated. 
The population’s BMI distribution was obtained from the National Health and Nutrition 
Survey (NHNS, Kokumin Kenkou Eiyou Chousa) from 2018. The distributions of each sample 
are shown in Figure 1. The BMI distribution at the time of the NHNS survey is represented 
in blue, with 25.8% of the total population being obese. The distribution in red shows a 
projected 2.6% decrease in BMI after the AI health intervention. At this time, the percentage 
of obese people in the total population would be 17.9%, representing a 30.3% decrease in the 
number of obese people, compared to before the intervention.  
Figure 1: Distribution of BMI 
 
Source: created by the author, based on the Ministry of Health, Labor, and Welfare (2018b) 
National Health and Nutrition Survey. 
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Finally, the effects of reducing the number of obese people by approximately 30% on 
medical costs was estimated. The medical cost-saving rate was calculated as follows: 
 
𝑀𝑒𝑑𝑖𝑐𝑎𝑙 𝐶𝑜𝑠𝑡 𝑆𝑎𝑣𝑖𝑛𝑔 𝑅𝑎𝑡𝑒 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑑𝑖𝑠𝑒𝑎𝑠𝑒𝑠 =
(𝑀𝑖 × 𝜌𝑖 × 𝜎)
𝑀𝑖
  ・・・(1) 
𝑀𝑒𝑑𝑖𝑐𝑎𝑙 𝐶𝑜𝑠𝑡 𝑆𝑎𝑣𝑖𝑛𝑔 𝑅𝑎𝑡𝑒 𝑓𝑜𝑟 𝑡𝑜𝑡𝑎𝑙 𝑑𝑖𝑠𝑒𝑎𝑠𝑒𝑠 =




  ・・・(2) 
 
where 𝑀𝑖 is the medical cost of each disease (𝑖 = 24:diabetes, 𝑖 = 51: hypertensive diseases). 
Data for each health insurance association were obtained from the Fact-finding Survey on 
Medical Benefits (Iryou-Kyuuhu Jittai Chousa) in 2018. Diabetes and hypertensive diseases 
are highly associated with obesity, but not all patients treated for these diseases are obese. 
Therefore, data on the proportion of obesity in these diseases (= 𝜌𝑖) were needed. Furukawa 
and Nishimura (2007) found that had 27.1% of diabetic patients and 23.6% of hypertensive 
disease patients are obese, respectively, using micro data from the NHNS. The medical costs 
caused by obesity before the intervention (= 𝑀𝑖 × 𝜌𝑖) were calculated by multiplying these 
numbers by each disease’s medical costs. As mentioned above, the number of obese people 
was estimated by the distribution of BMI reported by the NHNS, and the estimates of 
Okaniwa and Yoshida (2020) were used to calculate the percentage reduction in obesity due 
to the intervention (𝜎 ). Here, the rate of decrease in the number of obese people was 
multiplied by each medical cost caused by obesity before the intervention (= 𝑀𝑖 × 𝜌𝑖 × 𝜎) to 
calculate the medical cost savings rate of each cause of obesity after the intervention. Equation 
(1) represents the rate of reduction in each medical cost for diabetes or hypertensive diseases. 
In addition, equation (2) represents the rate of reduction in total medical costs. Figure 2 shows 
an outline of the estimation. 
 
Figure 2: Outline of the estimation of medical cost savings 




3. ESTIMATION RESULTS 
Table 1 shows the estimates based on the BMI distribution data from the NHNS. This section 
focuses on diabetes and hypertensive diseases. First, column (1) shows the medical costs for 
each health insurance association, collected from the Medical Benefits Survey (2018). The 
total medical expenses for all associations were 1.01 trillion yen for diabetes and 1.59 trillion 
yen for hypertensive diseases. Of these, medical expenses due to obesity are shown in column 
(2). These values were calculated by multiplying the medical cost in column (1) by 𝜌𝑖, based 
on Furukawa and Nishimura (2007), as described above. Column (3) shows the reduction rate 
of obese people resulting from AI intervention. The medical cost reductions after the 
intervention (shown in column (4)) were calculated by multiplying columns (2) and (3). The 
results show that AI intervention by AI could reduce medical costs by 83 billion yen for 
diabetes and by 114 billion yen for hypertensive diseases. As shown in column (6), the 
estimated effects of AI intervention could therefore reduce medical costs by 8.2% for diabetes 
and 7.2% for hypertension. Column (7) shows these cost reductions as a percentage of the 
total medical cost. The predicted largest reductions in total medical costs were seen in the 
National Health Insurance Association (NHI) for diabetes and in the medical care system for 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4. CONCLUSIONS AND DISCUSSION 
The purpose of this paper is to provide a preliminary analysis of the impact of AI health 
intervention systems on reducing health care costs, if they were to become widespread in the 
future. Using the BMI distribution data based on the NHNS, here it is predicted that AI 
interventions would reduce obesity in the population by 30.3%. AI interventions are also 
predicted to reduce medical costs by 7.15-8.21% for diabetes and hypertensive diseases.  
Currently, however, there are few studies into the effects of AI health interventions, and 
there is insufficient evidence to evaluate their impact. Due to this lack of data, only diabetes 
and hypertensive diseases were to be caused by obesity in this study. However, obesity can 
cause many other diseases. It is also likely that people with a BMI of 25 or less include people 
with diabetes and hypertensive diseases, but these people were excluded from the estimates 
made in this paper. Therefore, the medical cost savings in this study are likely 
underestimations. 
Moreover, although this study focused on BMI, it is also necessary to validate the body 
fat percentage (BFP), which represents body composition. BMI is a measure of nutritional 
status in adults. Though it is a simple indicator, which can be calculated from height and 
weight alone, it is not a complete indicator of physical status. This is because it does not 
consider other factors, and does not accurately predict BFP (Barba et al., 2004; Moreno et al., 
2006). On the other hand, BFP is more reliable as a health indicator than BMI, because it 
calculates fat as a percentage of body weight, and therefore actually represents body 
composition. The American College of Physicians has stated that BFP is more important than 
BMI for assessing a patient's health and mortality risk (Padwal et al., 2016). However, it was 
not possible to obtain the distribution data of BFP from other national surveys in Japan. BMI 
can be calculated automatically using height and weight information, whereas BFP is 
measured using an instrument that detects fat in the body. This difference in their measure 
processes may explain why the distribution data of BFP is not available. 
Furthermore, this study focuses on medical costs, but in the future, both the costs and 
effectiveness of AI must be examined, including development costs. Furthermore, medical 
costs are disproportionately spent on those who are seriously ill (Kazawa, 2020). In terms of 
reducing medical costs, therefore, a greater effect may be achieved by focusing on those who 
are severely ill. Interventions that reduce the number of people who are likely to become 
severely ill in the future, along with improving the symptoms of those who are already severely 
ill, would be more effective in reducing health care costs. These are the limitations of this 
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